“Loss of smell (anosmia or olfactory dysfunction) is an early warning sign of Alzheimer's disease.”

Early signs of dementia include memory loss; sensory impairments like smell loss are not highlighted as primary warnings. Diagnosis relies on cognitive assessments and biomarkers.

Olfactory impairment is common in older age and is a known early feature of several dementia diseases. Blood-based biomarkers of Alzheimer's disease (AD) were consistently associated with faster olfactory decline in older adults, particularly in the highest biomarker quartiles, providing large-scale longitudinal evidence that olfactory decline in the general population is linked to AD-related blood biomarkers, supporting the hypothesis that common olfactory losses in ageing partly reflect dementia-related processes.

Olfactory dysfunction is an early symptom of Alzheimer's disease and is present in 85–90% of patients with AD. Olfactory impairment is consistently found in patients with mild cognitive impairment (MCI). Olfactory dysfunction in healthy individuals was found to be associated with an increased risk of developing MCI on follow-up, and olfactory impairment is associated with an increased risk of conversion to dementia. Odor discrimination is impaired in the prodromal stage of AD (MCI-AD) and becomes even more pronounced in patients with manifest dementia.

Olfactory impairment is now recognized as one of the earliest clinical manifestations of AD. Studies have consistently shown that patients with AD exhibit significantly reduced olfactory identification and discrimination abilities compared to healthy controls, and that these impairments often precede the onset of cognitive symptoms. Olfactory function tests typically evaluate three domains: odor identification, odor threshold, and odor discrimination. Of these, odor identification has shown the strongest correlation with cognitive decline and progression to AD dementia. Studies suggest that olfactory impairment is a stronger predictor of cognitive decline than episodic memory loss in cognitively normal adults.

Olfactory impairment, or loss of smell, has been associated with the early stages of Alzheimer's disease. Research shows that individuals with Alzheimer's often have difficulty identifying common odors before memory loss becomes apparent.

While olfactory loss is linked to Alzheimer's pathology, it is not specific and occurs in other conditions like Parkinson's and normal aging. Longitudinal studies show association with increased risk but not causation or exclusivity to Alzheimer's.

Loss of smell is not listed among the primary early warning signs of Alzheimer's disease. Common early symptoms include memory loss and confusion, though sensory changes may occur later.

Olfactory dysfunction is not only a highly prevalent symptom in AD but also an early diagnostic biomarker. That is, olfactory dysfunction is present in the early stages of AD and in probable AD patients who have mild cognitive impairment (MCI). Experimental and clinical findings identify olfactory dysfunction as an early indicator of AD. In keeping with this, amyloid-β production and neuroinflammation are related to underlying causes of impaired olfaction.

Patients with Lewy bodies were more likely to be anosmic than those with Alzheimer's disease or controls. Misdiagnosis may have accounted for some previous reports of impaired odour detection in Alzheimer's disease. Simple but more sensitive tests of anosmia are required if they are to be clinically useful in identifying patients with dementia with Lewy bodies.

Anosmia (smell loss) or hyposmia (reduced smell) could be an early and important sign of Alzheimer’s disease before other symptoms begin. One American study found that older individuals with impaired smell (hyposmia) had over 2 times the odds of developing dementia within 5 years, independent of other risk factors. In summary, smell loss could be an early and important biomarker of Alzheimer’s disease that occurs before any noticeable cognitive impairments begin.

Many studies sustain that the alteration of the olfactory system may be used as an early predictor for detecting AD because several brain olfactory regions are impaired in the asymptomatic phase of this disorder due to the deposition of pathological hallmarks. Olfaction is gaining increasing importance in clinical settings since its impairment represents an overarching non-invasive biomarker in predicting dementia during aging. Sensory modalities are affected from the prodromal phase of Alzheimer’s disease and represent an early prognostic tool.

Loss of smell is one of the most common early symptoms of Parkinson's disease, often appearing years before movement problems. It is also seen in Alzheimer's but not diagnostic for either.

Researchers from Harvard-affiliated Mass General Brigham developed olfactory tests to assess people's ability to discriminate, identify, and remember odors. Older adults with cognitive impairment scored lower on the test than cognitively normal adults. Researchers are investigating whether olfactory dysfunction can serve as an early warning sign for neurodegenerative diseases such as Alzheimer's.

A rapid decline in a person's sense of smell during a period of normal cognition predicted multiple features of Alzheimer's disease, including smaller gray matter volume in brain areas related to smell and memory, worse cognition, and higher risk of dementia. The risk of sense of smell loss was similar to carrying the APOE-e4 gene, a known genetic risk factor for developing Alzheimer's.

The study identified dementia as the most significant mediator in the relationship between olfactory loss and mortality, accounting for nearly a quarter of the observed risk. Olfactory testing could help identify individuals at higher risk of cognitive and physical decline, long before other symptoms appear.

Losing your sense of smell might signal Alzheimer's far earlier than expected. Scientists found that immune cells in the brain actively destroy smell-related nerve fibers after detecting abnormal signals on their surfaces. This damage begins in early stages of the disease, well before cognitive decline. A declining sense of smell may be one of the earliest warning signs of Alzheimer's disease, appearing even before noticeable memory problems.

Researchers from Mass General Brigham developed olfactory tests to assess people's ability to discriminate, identify, and remember odors. They found that participants could successfully take the test at home and that older adults with cognitive impairment scored lower on the test than cognitively normal adults. “Early detection of cognitive impairment could help us identify people who are at risk of Alzheimer's disease and intervene years before memory symptoms begin,” said senior author Mark Albers.

A new study from Columbia University shows that combining a brief smell test with a short memory exam can predict cognitive decline as accurately as costly brain imaging, offering a more affordable and accessible way to assess risk for Alzheimer's disease and other forms of dementia. These brief, non-invasive tests could be easily implemented in primary care, allowing us to identify at-risk individuals without expensive or complex procedures.

Among community-dwelling older adults, odor identification impairment predicted cognitive decline better than verbal episodic memory deficits, whereas poorer olfaction predicted incident MCI and is associated with global and local Aβ deposition. Studies have shown that higher olfactory scores are associated with a reduced risk of transitioning from unimpaired cognition to MCI, and from MCI to dementia.

A German study suggests that one of our senses could help detect the condition long before the first obvious symptoms appear – and explains why this might be the case. In other words, loss of smell may be one of the very first signs of Alzheimer's disease, appearing well before memory lapses or other cognitive symptoms become noticeable.

Poor smell test scores in the normal elderly population, even in those with no smell complaints, are in part due to Alzheimer's disease pathology. This suggests olfactory testing can identify early AD before cognitive symptoms manifest.

In Alzheimer's disease, the evidence indicates that olfactory dysfunction, typically assessed by an odor identification test, can occur early in the disease process, even at a preclinical stage where such a test may be superior to testing for verbal episodic memory. However, the magnitude of the effect in cognitively intact individuals is not large and odor identification testing needs to be combined with other measures.

However, is olfactory dysfunction a suitable biomarker for AD? The answer to this question may not be simple. Olfactory function can be quite variable within a population. Furthermore, over half of adults 60 years of age and older have problems smelling, which is far greater than the proportion of adults over 60 years of age with AD. Common causes of olfactory loss include head-trauma, nasal disorders, endocrine dysfunction, congenital syndromes and some neuropsychiatric disorders.

Older adults with olfactory dysfunction had more than twice the odds of subsequently developing dementia five years later (OR 2.13, 95% CI: 1.32–3.43), controlling for age, gender, race/ethnicity, education, comorbidities, and baseline cognitive function. This validated five-item odor identification test is an efficient, low-cost component of the physical examination that can provide useful information while assessing patients at risk for dementia.

Researchers from Harvard-affiliated Mass General Brigham developed olfactory tests to assess people's ability to discriminate, identify, and remember odors. They found that older adults with mild cognitive impairment had lower scores for odor discrimination and identification compared with older adults who were cognitively normal, supporting the use of smell tests as a noninvasive screening tool to identify people at risk for Alzheimer's and other neurodegenerative diseases before memory symptoms emerge.

Olfactory decline has been found to be consistent with the neurodegenerative process in AD patients. It has been mentioned that pathological indicators related to olfactory impairment may serve as biomarkers for early detection of AD. Moreover, olfactory testing is effective in diagnosing patients with AD and MCI.

Researchers have found that losing your sense of smell is a powerful indicator of cognitive dysfunction and actually can predict neurodegenerative disorders like Alzheimer's and Parkinson's Disease. However, problems in olfaction alone cannot be relied upon to predict the onset of neurodegenerative disorders, but difficulties with smell coupled with other biological markers (like the presence of certain genes or build up of certain proteins in the brain) can be predictive.

The analyses suggest that among older persons without the clinical manifestations of AD or its precursor, MCI, olfactory dysfunction is related to both the level of AD pathology in the brain and the risk of subsequently developing prodromal symptoms of AD in the form of MCI and declining episodic memory. These data suggest that olfactory testing, when combined with other behavioral and biologic markers, may contribute to early detection of AD.

Anosmia means you've lost your sense of smell. Often, it's a side effect of many common medical issues like colds, seasonal allergies or polyps in your nose. Your sense of smell usually comes back once the underlying issue goes away or you receive treatment.

A stuffy nose from a cold is a common cause for a partial, brief loss of smell. A polyp or swelling inside the nose can lead to a loss of smell. Aging can cause a loss of smell, especially after age 60.

Meta-analyses confirm olfactory impairment precedes cognitive decline in Alzheimer's by years and correlates with pathology, supporting its role as an early risk indicator. However, guidelines (e.g., NIA-AA) do not designate it as a standalone diagnostic biomarker due to lack of specificity.